After Pulling IPO, Anacor Raises $50 Million In Equity Financing
This article was originally published in The Pink Sheet Daily
Executive Summary
Boron compound-focused biotech says proceeds should fund two years of operations.
You may also be interested in...
Anacor Reworks Collaboration With GSK For Potential Of Additional LeuRS Antibiotics
Six-year deal signed in 2007 may be extended if GSK decides to option additional leucyl-tRNA synthetase candidates discovered by Anacor.
Anacor Reworks Collaboration With GSK For Potential Of Additional LeuRS Antibiotics
Six-year deal signed in 2007 may be extended if GSK decides to option additional leucyl-tRNA synthetase candidates discovered by Anacor.
Anacor’s Topical Psoriasis Candidate Produces Strong Showing In Phase II
Boron-based anti-inflammatory drug targets TNF-a, other cytokine receptors.